DE69631588D1 - Benzolpiperidine/pyrrolidine zur verbesserung synaptischer reaktion - Google Patents

Benzolpiperidine/pyrrolidine zur verbesserung synaptischer reaktion

Info

Publication number
DE69631588D1
DE69631588D1 DE69631588T DE69631588T DE69631588D1 DE 69631588 D1 DE69631588 D1 DE 69631588D1 DE 69631588 T DE69631588 T DE 69631588T DE 69631588 T DE69631588 T DE 69631588T DE 69631588 D1 DE69631588 D1 DE 69631588D1
Authority
DE
Germany
Prior art keywords
compounds
subjects
ampa receptors
improving
benzolpiperidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69631588T
Other languages
English (en)
Other versions
DE69631588T2 (de
Inventor
A Rogers
Lena Nilsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Publication of DE69631588D1 publication Critical patent/DE69631588D1/de
Application granted granted Critical
Publication of DE69631588T2 publication Critical patent/DE69631588T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
DE69631588T 1995-06-02 1996-05-23 Benzolpiperidine/pyrrolidine zur verbesserung synaptischer reaktion Expired - Lifetime DE69631588T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/458,967 US5650409A (en) 1995-06-02 1995-06-02 Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US458967 1995-06-02
PCT/US1996/007607 WO1996038414A1 (en) 1995-06-02 1996-05-23 Benzoyl piperidines/pyrrolidines for enhancing synaptic response

Publications (2)

Publication Number Publication Date
DE69631588D1 true DE69631588D1 (de) 2004-03-25
DE69631588T2 DE69631588T2 (de) 2004-12-16

Family

ID=23822840

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69631588T Expired - Lifetime DE69631588T2 (de) 1995-06-02 1996-05-23 Benzolpiperidine/pyrrolidine zur verbesserung synaptischer reaktion

Country Status (13)

Country Link
US (2) US5650409A (de)
EP (1) EP0839134B1 (de)
JP (1) JP3464800B2 (de)
KR (2) KR100621499B1 (de)
AT (1) ATE259788T1 (de)
AU (1) AU708715B2 (de)
CA (1) CA2222976C (de)
DE (1) DE69631588T2 (de)
DK (1) DK0839134T3 (de)
ES (1) ES2216048T3 (de)
PL (1) PL187895B1 (de)
PT (1) PT839134E (de)
WO (1) WO1996038414A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU721936B2 (en) * 1996-04-03 2000-07-20 Regents Of The University Of California, The Benzoxazines for enhancing synaptic response
US5736543A (en) * 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response
WO1997039750A1 (en) * 1996-04-19 1997-10-30 The Regents Of The University Of California Treatment of mood/affective disorders by glutamatergic upmodulators
US6030968A (en) * 1996-09-17 2000-02-29 The Regents Of The University Of California Positive AMPA receptor modulation to enhance brain neurotrophic factor expression
US6110935A (en) * 1997-02-13 2000-08-29 The Regents Of The University Of California Benzofurazan compounds for enhancing glutamatergic synaptic responses
US6329368B1 (en) 1997-05-09 2001-12-11 The Regents Of The University Of California Endocrine modulation with positive modulators of AMPA type glutamate receptors
AU745641B2 (en) * 1997-10-27 2002-03-28 Cortex Pharmaceuticals, Inc. Treatment of schizophrenia with ampakines and neuroleptics
US5985871A (en) * 1997-12-24 1999-11-16 Cortex Pharmaceuticals, Inc. Benzoxazine compounds for enhancing synaptic response
US6943159B1 (en) 1998-02-18 2005-09-13 Neurosearch A/S Compounds and their use as positive AMPA receptor modulators
US6124278A (en) * 1998-04-03 2000-09-26 The Regents Of The University Of California Acylbenzoxazines for enhancing synaptic response
TWI232863B (en) * 2001-06-11 2005-05-21 Akzo Nobel Nv Benzoxazepine derivatives
JP4435562B2 (ja) * 2001-06-14 2010-03-17 ナームローゼ・フエンノートチヤツプ・オルガノン （ピリド／チエノ）−［ｆ］−オキサゼピン−５−オン誘導体
EP1448537A4 (de) * 2001-11-26 2005-05-04 Cortex Pharma Inc Carbonylbenzoxazinverbindungen zur verstärkung der glutamatergen synaptischen reaktionen
NZ540468A (en) 2003-01-13 2008-03-28 Univ California Method of treating cognitive decline due to sleep deprivation and stress using an AMPA receptor potentiator
US20060063707A1 (en) * 2004-09-17 2006-03-23 Lifelike Biomatic, Inc. Compositions for enhancing memory and methods therefor
TW200800959A (en) 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
KR20090098999A (ko) * 2007-01-03 2009-09-18 코텍스 파마슈티칼스, 인크. 글루타메이트에 의한 시냅스 반응을 향상시키기 위한 3-치환된-[1,2,3]벤조트리아지논 화합물
US8173644B2 (en) * 2007-01-03 2012-05-08 Les Laboratoires Servier 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
US8466199B2 (en) * 2007-03-21 2013-06-18 Emisphere Technologies, Inc. Allyloxy and alkyloxy benzoic acid delivery agents
US8013003B2 (en) * 2007-05-17 2011-09-06 Cortex Pharmaceuticals, Inc. Di-substituted amides for enhancing glutamatergic synaptic responses
CA2695742C (en) * 2007-08-10 2012-11-27 Rudolf Mueller Bicyclic amides for enhancing glutamatergic synaptic responses
US8119632B2 (en) 2007-08-10 2012-02-21 Cortex Pharmaceuticals, Inc. Bicyclic amide derivatives for enhancing glutamatergic synaptic responses
US20110218190A1 (en) * 2008-11-10 2011-09-08 The Regents Of The University Of California Therapeutic uses of ampa receptor modulators for treatment of motor dysfunction
US20130058915A1 (en) 2010-03-02 2013-03-07 Children's Medica Center Corporation Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
EP2801377B1 (de) 2011-03-04 2019-08-07 The Regents of The University of California Hydrogel enthaltend Zellen zur lokalen Freisetzung von Wachstumsfaktoren zur Rückgewinnung der Bewegungsfähigkeit nach einem Schlaganfall
WO2014117089A1 (en) 2013-01-25 2014-07-31 Case Western Reserve University Compositions and methods for the treatment of pervasive development disorders
BR112015031249A2 (pt) 2013-06-13 2017-07-25 Veroscience Llc método de tratamento, método para tratar um distúrbio metabólico ou um elemento chave do mesmo, método para normalizar um ritmo diário de liberação de dopamina no sumn, método para estimular a liberação de dopamina de neurônios dopaminérgicos no sumn de um indivíduo e composição farmacêutica
GB201510010D0 (en) 2015-06-09 2015-07-22 King S College London PDD and BPD compounds
GB201514928D0 (en) 2015-08-21 2015-10-07 King S College London PDD compounds
US20180339985A1 (en) 2015-08-21 2018-11-29 Femtogenix Limited Pdd compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3463855A (en) * 1965-05-12 1969-08-26 Johnson & Son Inc S C Insect repellent compositions of n-(meta-toluyl)-methyl piperidines
US3406177A (en) * 1965-05-12 1968-10-15 Johnson & Son Inc S C N-(meta-toluyl)-methylpiperidines
JPH01207284A (ja) * 1987-10-06 1989-08-21 Takeda Chem Ind Ltd アミド化合物
PT1156043E (pt) * 1992-07-24 2004-03-31 Univ California Drogas que aumentam as respostas sinapticas mediadas por receptores de ampa

Also Published As

Publication number Publication date
CA2222976A1 (en) 1996-12-05
US5650409A (en) 1997-07-22
ATE259788T1 (de) 2004-03-15
US5783587A (en) 1998-07-21
KR19990022249A (ko) 1999-03-25
CA2222976C (en) 2001-04-24
AU5929396A (en) 1996-12-18
JP3464800B2 (ja) 2003-11-10
KR20040004716A (ko) 2004-01-13
PL187895B1 (pl) 2004-10-29
AU708715B2 (en) 1999-08-12
PT839134E (pt) 2004-07-30
KR100444539B1 (ko) 2004-10-14
ES2216048T3 (es) 2004-10-16
DK0839134T3 (da) 2004-08-16
PL323667A1 (en) 1998-04-14
JP2001503012A (ja) 2001-03-06
EP0839134A1 (de) 1998-05-06
KR100621499B1 (ko) 2006-09-14
DE69631588T2 (de) 2004-12-16
EP0839134B1 (de) 2004-02-18
WO1996038414A1 (en) 1996-12-05

Similar Documents

Publication Publication Date Title
DE69631588D1 (de) Benzolpiperidine/pyrrolidine zur verbesserung synaptischer reaktion
DE69716414D1 (de) Benzoxazine zur erhöhung der synaptischen reaktionen
CA2138533A1 (en) Drugs that enhance synaptic responses mediated by ampa receptors
ATE194593T1 (de) 3-(3,4-dioxyphenyl)-pyrrolidine als inhibitonen der typ iv - phosphodiesterase zur behandlung von entzündungskrankheiten
DE69822344D1 (de) Benzoxazin-derivate zur erhöhung der synaptischen reaktion
DE69834590D1 (de) Benzofurazanderivate und deren verwendung zur verbesserung glutaminerger synaptischer antworten
SE9102688L (sv) Foerfarande foer behandling av avfallsvatten med avseende paa organiska foeroreningar med organiskt modifierade smektitlerakompositioner
DE69910552D1 (de) Acylbenzoxazine zur erhöhung der synaptischen reaktion(en)
EA200400584A1 (ru) Соединения карбонилбензоксазина для усиления глутаматергических синаптических ответов
ATE312914T1 (de) Rdgb-proteine
CA2249654A1 (en) Benzoxazines for enhancing synaptic response
KR960031593A (ko) 타타르산을 이용한 수두 바이러스의 활성 증진 방법

Legal Events

Date Code Title Description
8364 No opposition during term of opposition